Compare Amgen, Inc. (AMGN) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Strategy Inc. — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Strategy Inc. trades at $91.27 (market cap $33.86B). The key difference: Amgen, Inc. is far larger — about 5.8× Strategy Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| AMGN | MSTR | |
|---|---|---|
Market Cap | $196.12B | $33.86B |
Sector | Health | Technology |
52-Week High | $388.16 | $455.90 |
52-Week Low | $271.18 | $82.31 |
Enterprise Value | $241.41B | $48.89B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MSTR stock trades at $94.64, up 0.8% today, but remains in a bearish technical trend with resistance near $96. The company reported a net loss of $3.85 billion in 2025, with a negative net income margin of -806.35%, while revenue was $477.23 million. Recent news highlights the company's shift in Bitcoin strategy, including a $216 million sale to fund dividends, raising questions about its business model sustainability amid Bitcoin price volatility.
Wall Street analysts maintain a bullish consensus with a $237.63 price target and 62% buy ratings, but high valuation multiples and persistent losses pose significant risks. Investment appeal hinges on Bitcoin's performance and the company's ability to manage its substantial debt, with current cash flow trends showing reliance on financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
